Understanding how ovarian cancer can come back after chemotherapy
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse
This study is looking into why ovarian cancer sometimes comes back after treatment, especially focusing on certain stubborn cancer cells that survive chemotherapy, and it aims to find new ways to stop this from happening so that patients can have better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | San Diego State University NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11114626 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind ovarian cancer relapse after chemotherapy, focusing on a specific group of resistant cancer cells known as tumor-initiating cells (TICs). The study aims to understand how these cells survive treatment and contribute to the recurrence of the disease. By exploring the role of alternative NF-kB signaling and the tumor microenvironment, researchers hope to identify new therapeutic strategies that could prevent relapse and improve patient outcomes. Patients may benefit from insights that could lead to more effective treatments targeting these resistant cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who have been treated for ovarian cancer and are at risk of relapse.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent ovarian cancer from returning after initial treatment.
How similar studies have performed: Previous research has shown promise in targeting tumor-initiating cells in other cancers, suggesting potential for success in this area as well.
Where this research is happening
San Diego, United States
- San Diego State University — San Diego, United States (Active)
Researchers
- Principal investigator: House, Carrie Danielle — San Diego State University
- Study coordinator: House, Carrie Danielle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.